Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Impact of rilzabrutinib on gene-expression of inflammatory factors in patients with warm autoimmune hemolytic anemia who participated in the Phase 2B lumina 2 study

Alessandro Lucchesi, Nicola Cooper, Bruno Fattizzo, Lei Wang, Eric Boitier, Cintia C. Palu, Dimitri Carene, Vincent Mikol, Ahmed Daak, David Kuter

Blood (2025) 146 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2025-2881

Published: 2025

Journal Articles

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

Blood (2025) 146 (Supplement 1): 1100.

https://doi.org/10.1182/blood-2025-1100

Published: 2025

Journal Articles

Phase 3 Study to evaluate the efficacy and safety of rilzabrutinib in primary warm autoimmune hemolytic anemia (wAIHA): LUMINA 3 Study design

David Kuter, Quentin A. Hill, Bruno Fattizzo, Deepthi Jayawardene, Ahmed Daak

Blood (2025) 146 (Supplement 1): 1123.

https://doi.org/10.1182/blood-2025-1123

Published: 2025

Journal Articles

Characterization of bone marrow B-cells in patients with warm autoimmune hemolytic anemia by single-cell analysis

Bruno Fattizzo, Francesca Lazzaroni, Filippo Viviani, Emanuele Calvi, Giacinto Luca Pedone, Marta Bortolotti, Akihiro Maeda, Marta Lionetti, Alessio Marella, Antonio Matera, Niccolo Bolli, Francesco Passamonti, Wilma Barcellini, Matteo Claudio Da Vià

Blood (2025) 146 (Supplement 1): 1122.

https://doi.org/10.1182/blood-2025-1122

Published: 2025

Journal Articles

Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety.

Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard Kelly, Roochi Trikha, Yasutaka Ueda, Jun-ichi Nishimura, Christopher Patriquin, Alexander Röth, Petra Muus, Jens Panse, Miguel Gómez Álvarez, Alexandra Pike, Talha Munir, Shreyans Gandhi, Austin Kulasekararaj

Blood (2025) 146 (Supplement 1): 1114.

https://doi.org/10.1182/blood-2025-1114

Published: 2025

Journal Articles

Fatigue, hemoglobin, and inflammatory markers in warm autoimmune hemolytic anemia: Analysis from a phase 2b trial of rilzabrutinib (LUMINA2)

David Kuter, Nicola Cooper, Mattea Orsini, Jerome Msihid, Laurence Pollissard, Matias Cordoba, Ahmed Daak, Marek Wardecki, Lei Wang, Bruno Fattizzo

Blood (2025) 146 (Supplement 1): 1105.

https://doi.org/10.1182/blood-2025-1105

Published: 2025

Journal Articles

Luspatercept for the treatment of transfusion-dependent anemia in patients with myelodysplastic neoplasms with del5q, refractory/resistant/intolerant to prior treatments (QOL-ONE Phoenix)

Blood (2025) 146 (Supplement 1): 5631.

https://doi.org/10.1182/blood-2025-5631

Published: 2025

Journal Articles

Early access program for danicopan (ALXN2040) as add-on treatment to eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH): Preliminary data from the Italian real-world survey.

Elisabetta Metafuni, Antonio De Vivo, Andrea Patriarca, Marta Venturi, Simona Raso, Amalia Figuera, Antonella Sau, Maria Bruna Greve, Milena Mirabile, Olga Mulas, Eloise Beggiato, Antonella Carbone, Martina Salvatori, Anna Paola Iori, Simona Sica, Wilma Barcellini, Bruno Fattizzo

Blood (2025) 146 (Supplement 1): 4665.

https://doi.org/10.1182/blood-2025-4665

Published: 2025

Journal Articles

Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

Bruno Fattizzo, Henrik Frederiksen, Alessandro Lucchesi, Bing Han, Catherine Broome, Nicola Cooper, Joan Cid, Frederick Chen, Amitabha Mazumder, Míriam Vara Pampliega, Deepthi Jayawardene, Heidi Krenz, Jing Zhao, Ahmed Daak, David Kuter

Blood (2025) 146 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2025-4655

Published: 2025

Journal Articles

Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study

Blood (2025) 146 (Supplement 1): 2685.

https://doi.org/10.1182/blood-2025-2685

Published: 2025

Journal Articles

Distinct patterns of bone marrow complement and immunoglobulin deposition define unique clinicopathologic phenotypes in myelodysplastic neoplasms

Giacinto Luca Pedone, Claudia Leoni, Marta Bortolotti, Wilma Barcellini, Matteo Claudio Da Vià, Bruno Fattizzo

Blood (2025) 146 (Supplement 1): 7368.

https://doi.org/10.1182/blood-2025-7368

Published: 2025

Journal Articles

Decoding the ektacytometric landscape of hereditary spherocytosis: Insights from 204 cases

Anna Zaninoni, Elisa Fermo, cristina vercellati, Anna Marcello, Dario Consonni, Bruno Fattizzo, Wilma Barcellini, Paola Bianchi

Blood (2025) 146 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2025-2889

Published: 2025

Journal Articles

Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice

Bruno Fattizzo, Francesco Versino, Wilma Barcellini

Blood (2025) 146 (4): 411–421.

https://doi.org/10.1182/blood.2024027574

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia

Eloy Roman, Bruno Fattizzo, Merrill Shum, Wahid Hanna, Steven R. Lentz, Sergio Schusterschitz S. Araujo, Mohammed Al-Adhami, Federico V. Grossi, Morie A. Gertz

Blood (2025) 145 (4): 397–408.

https://doi.org/10.1182/blood.2023022549

Published: 2025

Includes: Supplemental data

Journal Articles

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Amer M. Zeidan, Mikkael A. Sekeres, Hanny Al-Samkari, Hetty E. Carraway, Amy E. DeZern, Moshe Mittelman, Meredith Little, Vanessa Beynon, Xiaoshu Dai, Sal Sommakia, Jenny M. Despotovic, Parija Patel, Melissa Dibacco, Bruno Fattizzo, Eytan M. Stein, David Sallman, Austin G. Kulasekararaj, Uwe Platzbecker, Pierre Fenaux

Blood (2024) 144 (Supplement 1): 6708.

https://doi.org/10.1182/blood-2024-203073

Published: 2024

Journal Articles

Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Blood (2024) 144 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2024-204659

Published: 2024

Journal Articles

Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center

Blood (2024) 144 (Supplement 1): 1696.

https://doi.org/10.1182/blood-2024-208828

Published: 2024

Journal Articles

Effect of Obexelimab on the Production of Anti-Erythrocyte Autoantibodies in Vitro By Mitogen Stimulated Direct Anti-Globulin Test (MS-DAT)

Bruno Fattizzo, Mark Matijevic, Michele Youd, Xiao Feng, Wilma Barcellini, Anna Zaninoni

Blood (2024) 144 (Supplement 1): 5215.

https://doi.org/10.1182/blood-2024-198318

Published: 2024

Journal Articles

Evaluation of Obexelimab in Patients with Warm Autoimmune Hemolytic Anemia: Preliminary Results from an Open Label Phase 2 Study

Bruno Fattizzo, Gillian Evans, Audrey Wells, Allen Poma, Shauna Quinn, Dale Zhang, Mason Yamashita, Tanya Z. Fischer

Blood (2024) 144 (Supplement 1): 5212.

https://doi.org/10.1182/blood-2024-206100

Published: 2024

Journal Articles

Aplastic Anemia in the Elderly: Treatment Patterns and Outcomes from an International Observational Study

Bruno Fattizzo, Carmelo Gurnari, Sabrina Giammarco, Antony Ricchiuti, Hussein Awada, Marta Bortolotti, Giacinto Luca Pedone, Francesco Versino, Dario Consonni, Roochi Trikha, Shreyans Gandhi, Simona Sica, Jaroslaw Maciejewski, Austin G. Kulasekararaj, Wilma Barcellini

Blood (2024) 144 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2024-198321

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of rilzabrutinib on gene-expression of inflammatory factors in patients with warm autoimmune hemolytic anemia who participated in the Phase 2B lumina 2 study

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

Phase 3 Study to evaluate the efficacy and safety of rilzabrutinib in primary warm autoimmune hemolytic anemia (wAIHA): LUMINA 3 Study design

Characterization of bone marrow B-cells in patients with warm autoimmune hemolytic anemia by single-cell analysis

Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety.

Fatigue, hemoglobin, and inflammatory markers in warm autoimmune hemolytic anemia: Analysis from a phase 2b trial of rilzabrutinib (LUMINA2)

Luspatercept for the treatment of transfusion-dependent anemia in patients with myelodysplastic neoplasms with del5q, refractory/resistant/intolerant to prior treatments (QOL-ONE Phoenix)

Early access program for danicopan (ALXN2040) as add-on treatment to eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH): Preliminary data from the Italian real-world survey.

Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study

Distinct patterns of bone marrow complement and immunoglobulin deposition define unique clinicopathologic phenotypes in myelodysplastic neoplasms

Decoding the ektacytometric landscape of hereditary spherocytosis: Insights from 204 cases

Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice

Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center

Effect of Obexelimab on the Production of Anti-Erythrocyte Autoantibodies in Vitro By Mitogen Stimulated Direct Anti-Globulin Test (MS-DAT)

Evaluation of Obexelimab in Patients with Warm Autoimmune Hemolytic Anemia: Preliminary Results from an Open Label Phase 2 Study

Aplastic Anemia in the Elderly: Treatment Patterns and Outcomes from an International Observational Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only